Inventor · disambiguated record
Douglas Hay
Also filed as: HAY DOUGLAS · HAY DOUGLAS W P
4 granted patents·5 pending applications·7 citations·filing 2015–2024
69Inventor score
Top patents by PatentIndex Score
9 records- 0187US11701355B2Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)TENAX THERAPEUTICS INC·Filed 2022·Granted Jul 18, 2023·1 cites·10 claims
- 0287US11607412B2Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)TENAX THERAPEUTICS INC·Filed 2021·Granted Mar 21, 2023·2 cites·8 claims
- 0381US11969424B2Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)TENAX THERAPEUTICS INC·Filed 2020·Granted Apr 30, 2024·1 cites·20 claims
- 0477US11213524B2Pharmaceutical compositions for subcutaneous administration of levosimendanTENAX THERAPEUTICS INC·Filed 2019·Granted Jan 4, 2022·3 cites·19 claims
- 0577US2024269134A1LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)TENAX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0657US2025064799A1Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fractionTENAX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0753US2022096470A1Pharmaceutical compositions for subcutaneous administration of levosimendanTENAX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 0848US2023287095A1Humanized anti-emap ii therapeutic antibodiesALLINAIRE THERAPEUTICS LLC·Filed 2021·Application pending·0 cites
- 0933US2015374689A1Use of Levosimendan to Treat Left Ventricular Systolic Dysfunction in Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary BypassTENAX THERAPEUTICS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Douglas Hay files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →